Stock Research: Cipla

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Cipla

NSI:CIPLA INE059A01026
46
  • Value
    49
  • Growth
    29
  • Safety
    Safety
    96
  • Combined
    73
  • Sentiment
    13
  • 360° View
    360° View
    46
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Cipla Limited is a global pharmaceutical company that develops, manufactures, and markets a wide range of branded and generic formulations and APIs. The company operates in the pharmaceuticals and new ventures segments. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system (CNS) areas. Its main geographical segments include India, the United States, South Africa, and the Rest of the World. In the last fiscal year, the company had a market cap of $13,867 million, profits of $2,035 million, and revenue of $3,224 million with 30313 employees.

more
Index
CNX Nifty 50
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 61 61 65
Growth
29 53 51 53
Safety
Safety
96 89 77 57
Sentiment
13 89 47 98
360° View
360° View
46 95 76 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
39 54 59 74
Opinions Change
3 95 50 69
Pro Holdings
n/a 80 67 80
Market Pulse
50 78 21 73
Sentiment
13 89 47 98
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 61 61 65
Growth
29 53 51 53
Safety Safety
96 89 77 57
Combined
73 89 79 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
40 48 50 65
Price vs. Earnings (P/E)
49 60 64 65
Price vs. Book (P/B)
50 52 60 64
Dividend Yield
58 48 34 34
Value
49 61 61 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
51 37 34 23
Profit Growth
15 49 73 58
Capital Growth
49 45 57 75
Stock Returns
41 61 49 45
Growth
29 53 51 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
86 82 74 54
Refinancing
77 62 72 78
Liquidity
92 68 60 39
Safety Safety
96 89 77 57

Similar Stocks

Discover high‑ranked alternatives to Cipla and broaden your portfolio horizons.

SBI Life Insurance

NSI:SBILIFE
Country: India
Industry: Life & Health Insurance
Size: Medium
Full Stock Analysis

Canara Bank

NSI:CANBK
Country: India
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Aurobindo Pharma

NSI:AUROPHARMA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Oil and Natural Gas

NSI:ONGC
Country: India
Industry: Oil & Gas Integrated
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This stock is a good value with safe financing, but has low growth and negative sentiment. It is a good option for a cautious value investor looking for stability but who can tolerate low momentum and skeptical professional opinion.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: